A randomized phase <scp>III</scp> study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: <scp>JMTO LC09</scp>‐01

20231 citationsJournal Articlegold Open Access

Authors

The prematurely terminated study did not show the benefit of two cytotoxic agents over single-agent therapy for previously treated NSCLC patients.

No poverty

Published in: Thoracic Cancer

Volume 14, Issue 29, pp. 2941-2949

Field-Weighted Citation Impact: 0.27